PA8484901A1 - Combinaciones para la diabetes - Google Patents

Combinaciones para la diabetes

Info

Publication number
PA8484901A1
PA8484901A1 PA19998484901A PA8484901A PA8484901A1 PA 8484901 A1 PA8484901 A1 PA 8484901A1 PA 19998484901 A PA19998484901 A PA 19998484901A PA 8484901 A PA8484901 A PA 8484901A PA 8484901 A1 PA8484901 A1 PA 8484901A1
Authority
PA
Panama
Prior art keywords
combinations
antidiabetic agent
diabetes
sulfonilurea
optionally
Prior art date
Application number
PA19998484901A
Other languages
English (en)
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8484901A1 publication Critical patent/PA8484901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

LAS COMBINACIONES DE UN AGENTE ANTIDIABÉTICO DE GLITAZONA Y UN AGENTE ANTIDIABÉTICO DE BIGUANIDA, Y OPTATIVAMENTE UN AGENTE ANTIDIABÉTICO DE SULFONILUREA, SON ÚTILES PARA TRATAR LA DIABETES MELLITUS Y MEJORAR EL CONTROL GLUCÉMICO.
PA19998484901A 1998-11-09 1999-10-29 Combinaciones para la diabetes PA8484901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/189,132 US6011049A (en) 1997-02-19 1998-11-09 Combinations for diabetes

Publications (1)

Publication Number Publication Date
PA8484901A1 true PA8484901A1 (es) 2000-09-29

Family

ID=22696072

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998484901A PA8484901A1 (es) 1998-11-09 1999-10-29 Combinaciones para la diabetes

Country Status (20)

Country Link
US (1) US6011049A (es)
EP (2) EP1128834B1 (es)
JP (1) JP2002529417A (es)
AR (1) AR020973A1 (es)
AT (1) ATE293980T1 (es)
AU (1) AU5347399A (es)
CA (1) CA2345524C (es)
CO (1) CO5150152A1 (es)
CR (1) CR6128A (es)
DE (1) DE69925019T2 (es)
DK (1) DK1128834T3 (es)
ES (1) ES2241305T3 (es)
GT (1) GT199900158A (es)
HN (1) HN1999000184A (es)
PA (1) PA8484901A1 (es)
PE (1) PE20001235A1 (es)
PT (1) PT1128834E (es)
SI (1) SI1128834T1 (es)
UY (1) UY25791A1 (es)
WO (1) WO2000027401A1 (es)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
KR20070053264A (ko) 1998-09-09 2007-05-23 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족억제제
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
RU2002126616A (ru) 2000-03-08 2004-03-20 Метабэйсис Терапьютикс, Инк. (Us) Новые арильные ингибиторы фруктозо-1, 6-бисфосфатазы
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6610272B1 (en) 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
JP2004516234A (ja) * 2000-05-01 2004-06-03 エアロファーム テクノロジー インコーポレイテッド コア製剤
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
JP2004510716A (ja) * 2000-10-02 2004-04-08 ユーエスヴイ　リミテッド メトフォルミン含有持続性放出薬理組成物とその製造方法
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
EP1349531A1 (en) 2001-01-12 2003-10-08 Sun Pharmaceuticals Industries Ltd. Spaced drug delivery system
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
FR2823225B1 (fr) * 2001-04-04 2004-09-17 Pierre Desreumaux Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant
CA2443632C (en) * 2001-04-10 2011-05-03 Sun Pharmaceutical Industries Limited Timed pulse release composition
US20040156903A1 (en) * 2002-05-22 2004-08-12 Abrams Andrew L.. Metering and packaging of controlled release medication
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
WO2003005995A1 (en) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated Core formulation comprising pioglitazone hydrochloride and a biguanide
AU2001273290B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. Core formulation comprising troglitazone and a biguanide
JP2004536841A (ja) * 2001-07-10 2004-12-09 エアロファーム テクノロジー インコーポレイテッド コア製剤
WO2003007951A1 (en) * 2001-07-17 2003-01-30 N-Gene Research Laboratories Inc. A synergistic pharmaceutical combination for the prevention or treatment of diabetes
JP4965060B2 (ja) * 2001-07-27 2012-07-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング バウヒニア抽出物
ATE378054T1 (de) * 2001-07-30 2007-11-15 Mitsubishi Pharma Corp Mittel zu linderung von hyperglykämie nach dem essen
FR2832633B1 (fr) * 2001-11-28 2004-09-24 Lipha Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
FR2834640B1 (fr) * 2002-01-11 2004-09-24 Lipha Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete
ES2284829T3 (es) * 2002-01-25 2007-11-16 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica que se usa para controlar la glucosa en sangre en pacientes con diabetes de tipo 2.
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004028524A1 (ja) * 2002-09-26 2004-04-08 Eisai Co., Ltd. 併用医薬
IN192749B (es) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
PT1558220E (pt) * 2003-07-24 2010-03-12 Rasendrakumar Jha Composições orais para tratamento da diabetes
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005041962A1 (en) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
KR20070068407A (ko) * 2004-10-25 2007-06-29 노파르티스 아게 Ｄｐｐ―ｉｖ 억제제, ｐｐａｒ 항당뇨병제 및메트포르민의 조합물
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
WO2007011524A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
MXPA05010977A (es) * 2005-10-12 2007-04-11 Abdala Leopoldo Espinosa Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
MXPA05014092A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
US20070249561A1 (en) * 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
PL2084124T3 (pl) 2006-10-02 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę
JP5424887B2 (ja) 2006-11-08 2014-02-26 チョンシー ユー ペプチド及び関連化合物の経皮送達システム
WO2008072032A1 (en) 2006-12-10 2008-06-19 Chongxi Yu Transdermal delivery systems of beta-lactam antibiotics
CN109503446B (zh) 2007-01-15 2021-08-20 于崇曦 维生素a酸类和类维生素a酸化合物的前药
EP3176169A1 (en) 2007-01-31 2017-06-07 Chongxi Yu Positively charged water-soluble prodrugs of 1h-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN101711107A (zh) * 2007-04-11 2010-05-19 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
AU2007354632B2 (en) 2007-06-04 2014-06-26 Techfields Inc Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses
RU2569749C2 (ru) * 2007-08-17 2015-11-27 Бёрингер Ингельхайм Интернациональ Гмбх Производные пурина, предназначенные для применения для лечения заболеваний, связанных с баф (белок-активатор фибробластов)
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
AR071175A1 (es) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US8476008B2 (en) * 2008-07-23 2013-07-02 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
US20110144055A1 (en) * 2008-09-04 2011-06-16 Rozmanith Anthony I Health Care
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX337730B (es) * 2008-12-04 2016-03-16 Chongxi Yu Composiciones de alta penetracion y sus aplicaciones.
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BRPI1009141A2 (pt) 2009-03-11 2016-03-08 Omeros Corp composições e métodos para profilaxia e tratamento de vícios
SI2424356T1 (en) 2009-04-29 2018-01-31 Armarin Pharmaceuticals Ireland Limited A stable pharmaceutical composition and procedures for its use
KR101357438B1 (ko) 2009-04-29 2014-02-06 아마린 코포레이션 피엘씨 Ｅｐａ 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법
PL2427475T3 (pl) 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US9969751B2 (en) 2009-06-10 2018-05-15 Techfields Pharma Co., Ltd. High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
KR20210033559A (ko) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
BR112012026005A2 (pt) * 2010-04-13 2015-09-08 Nucitec Sa De Cv composições e métodos para tratar diabetes do tipo ii e distúrbios relacionados
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
AU2011257964B2 (en) 2010-05-24 2014-10-30 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
EP2585101A1 (en) 2010-06-24 2013-05-01 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
KR20220130239A (ko) 2012-01-18 2022-09-26 테크필즈 파마 코., 엘티디. 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
NL2015957B1 (en) 2015-12-14 2017-06-29 Scala Pharma B V Compositions and methods for inducing beige or brown fat tissue.
EP3184106A1 (en) 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Growth differentiation factor 15 as biomarker for metformin
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
JP7020756B2 (ja) 2018-09-24 2022-02-16 アマリン ファーマシューティカルズ アイルランド リミテッド 対象の心血管イベントのリスクを低減する方法
NL2024493B1 (en) 2019-12-16 2021-09-02 Logick Energetics B V Pharmaceutical composition for preventing or stopping metastases
WO2021125951A1 (en) 2019-12-18 2021-06-24 Logick Energetics B.V. Pharmaceutical composition for use in preventing or stopping metastases
NL2025335B1 (en) 2020-04-10 2021-10-26 Logick Energetics B V Pharmaceutical composition for treatment of corona virus infection
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
NL2028476B1 (en) 2021-06-17 2022-12-27 Logick Energetics B V Pharmaceutical composition for increasing mitochondrial activity and/or improving adiponectin production
NL2029634B1 (en) 2021-11-04 2023-06-02 Logick Energetics B V Pharmaceutical composition for increasing mitochondrial activity and/or improving adiponectin production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment

Also Published As

Publication number Publication date
DE69925019T2 (de) 2006-03-02
ES2241305T3 (es) 2005-10-16
WO2000027401A1 (en) 2000-05-18
CR6128A (es) 2000-11-30
EP1128834A1 (en) 2001-09-05
CO5150152A1 (es) 2002-04-29
US6011049A (en) 2000-01-04
CA2345524A1 (en) 2000-05-18
EP1128834B1 (en) 2005-04-27
UY25791A1 (es) 2001-03-16
DK1128834T3 (da) 2005-07-04
PT1128834E (pt) 2005-07-29
PE20001235A1 (es) 2000-11-08
EP1514550A2 (en) 2005-03-16
CA2345524C (en) 2005-09-20
JP2002529417A (ja) 2002-09-10
SI1128834T1 (es) 2005-08-31
GT199900158A (es) 2001-03-10
AU5347399A (en) 2000-05-29
ATE293980T1 (de) 2005-05-15
EP1514550A3 (en) 2009-04-29
HN1999000184A (es) 2000-02-10
AR020973A1 (es) 2002-06-05
DE69925019D1 (de) 2005-06-02

Similar Documents

Publication Publication Date Title
PA8484901A1 (es) Combinaciones para la diabetes
PA8447401A1 (es) Combinaciones para diabetes de sulfonilurea - glitazona
BR9708873B1 (pt) mistura fungicida, e, processo para controlar fungos nocivos.
BR9813682B1 (pt) mistura fungicida, e, processo para controlar fungos nocivos.
DE4496456D2 (de) Endoskop mit bewegbarem vorderen Endbereich
FI900125A (fi) Positivt arbetande straolningskaenslig blandning innehaollande en flerfunktionell a-diazo-b-ketoester, foerfarande foer dess framstaellning och staolningskaensligt registreringsmaterial som innehaoller denna blandning.
ES553819A0 (es) Dispositivo regulador trabajando electromagneticamente, para elementos de maniobra, moviles de modo oscilante.
BR9804932A (pt) Aparelho e método para confecção de modo seletivo de perfurações longitudinais em materiais em tira.
GB9828270D0 (en) An electro kinetic geosynthetic structure
DE69015024D1 (de) Unter Feldeffekt-Emission arbeitende Schaltanordnung und deren Herstellungsverfahren.
BR9813681B1 (pt) mistura fungicida, e, processo para controlar fungos nocivos.
BR9813664B1 (pt) mistura fungicida, e, processo para controlar fungos nocivos.
BR0111290B1 (pt) mistura de estabilizantes, composição compreendendo a mesma e método para estabilizar um material orgánico.
DE69020669D1 (de) Vulkanisierbare Kautschukmischungen, welche Hydroxyaryl-substituierte Monomaleimide enthalten.
ECSP993207A (es) Combinaciones para la diabetes
ECSP982417A (es) Combinaciones para diabetes de sulfonilurea glitazona
BR9809473B1 (pt) mistura fungicida, e, processo para controlar fungos nocivos.
NL193917B (nl) Geïmpregneerde afgeefkathode, en vervaardigingsmethode daarvoor.
KR900011936A (ko) 폴리에스테르 섬유의 처리 방법, 그 방법에 의해 처리된 폴리에스테르 섬유 및 그 폴리에스테르 섬유와 니트릴기-함유 고포화 공중합체 고무로 구성된 복합 재료
DE69411979D1 (de) Ventilblock für eine I.S.-Maschine
SI1351694T1 (sl) Pospesevanje celicne regeneracije in/ali celicne diferenciacije z nepresnovljivim sladkorjem in polimernim absorbentom
DE60017536D1 (de) Steuervorrichtung mit mehreren stabilen Positionen, insbesondere fur Zigarrenanzünder
FI893986A (fi) Nytt glykopeptidantibiotikum, decaplanin, foerfarande foer dess framstaellning och dess anvaendning som laekemedel.
AR005461A1 (es) Composicion para mejorar el control glicemico
ES1037275U (es) Util para ascension y trabajo en palmeras.